Zhang and co-workers have shown that BRT has the capacity to down-regulate PD-L1 expression in various cancer cell types (HeLa, Hep3B, HCT116, A549), and they suggested that the compound could directly bind to PD-L1, on the basis of a molecular docking analysis [67]. The gene discussed is CD274; the disease is cancer.